US3608070A - New surgical dressing - Google Patents
New surgical dressing Download PDFInfo
- Publication number
- US3608070A US3608070A US866028A US3608070DA US3608070A US 3608070 A US3608070 A US 3608070A US 866028 A US866028 A US 866028A US 3608070D A US3608070D A US 3608070DA US 3608070 A US3608070 A US 3608070A
- Authority
- US
- United States
- Prior art keywords
- dressing
- skin
- excipient
- parts
- percent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000013008 thixotropic agent Substances 0.000 claims abstract description 12
- 239000002904 solvent Substances 0.000 claims abstract description 11
- 239000004014 plasticizer Substances 0.000 claims abstract description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 10
- ULQISTXYYBZJSJ-UHFFFAOYSA-N R-12-HOA Natural products CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940114072 12-hydroxystearic acid Drugs 0.000 claims abstract description 3
- 150000002148 esters Chemical class 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000000440 bentonite Substances 0.000 claims description 6
- 229910000278 bentonite Inorganic materials 0.000 claims description 6
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000005995 Aluminium silicate Substances 0.000 claims description 4
- 235000012211 aluminium silicate Nutrition 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims description 3
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims description 3
- 239000008119 colloidal silica Substances 0.000 claims description 3
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims description 3
- 239000011347 resin Substances 0.000 abstract description 12
- 229920005989 resin Polymers 0.000 abstract description 12
- 229920001577 copolymer Polymers 0.000 abstract description 10
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 6
- 239000000194 fatty acid Substances 0.000 abstract description 6
- 229930195729 fatty acid Natural products 0.000 abstract description 6
- 150000004665 fatty acids Chemical class 0.000 abstract description 6
- 125000004432 carbon atom Chemical group C* 0.000 abstract description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 11
- 239000003814 drug Substances 0.000 description 9
- 235000019441 ethanol Nutrition 0.000 description 9
- -1 benzyl alcohol, quaternary ammonium compounds Chemical class 0.000 description 7
- 239000002674 ointment Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 6
- 229940117958 vinyl acetate Drugs 0.000 description 6
- 239000011269 tar Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 206010048768 Dermatosis Diseases 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 230000009974 thixotropic effect Effects 0.000 description 3
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 2
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 description 2
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- HNOOXWDWUSLXOB-UHFFFAOYSA-N biclotymol Chemical compound CC(C)C1=CC(Cl)=C(C)C(CC=2C(=C(C(C)C)C=C(Cl)C=2C)O)=C1O HNOOXWDWUSLXOB-UHFFFAOYSA-N 0.000 description 2
- 229960004093 biclotymol Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000003537 radioprotector Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- FDHNLHLOJLLXDH-JIYHLSBYSA-N (e)-3-(3-hydroxy-4-methoxyphenyl)-1-[2-hydroxy-6-methoxy-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxyphenyl]prop-2-en-1-one Chemical compound C1=C(O)C(OC)=CC=C1\C=C\C(=O)C(C(=C1)OC)=C(O)C=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 FDHNLHLOJLLXDH-JIYHLSBYSA-N 0.000 description 1
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 1
- KFZXVMNBUMVKLN-UHFFFAOYSA-N 4-chloro-5-methyl-2-propan-2-ylphenol Chemical compound CC(C)C1=CC(Cl)=C(C)C=C1O KFZXVMNBUMVKLN-UHFFFAOYSA-N 0.000 description 1
- 241000157282 Aesculus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 240000008299 Pinus lambertiana Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000779819 Syncarpia glomulifera Species 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- YUTJCNNFTOIOGT-UHFFFAOYSA-N anthracene-1,8,9-triol Chemical compound C1=CC(O)=C2C(O)=C3C(O)=CC=CC3=CC2=C1 YUTJCNNFTOIOGT-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940110716 cicatrizants Drugs 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 239000011280 coal tar Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical group O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229940011399 escin Drugs 0.000 description 1
- 229930186222 escin Natural products 0.000 description 1
- 229940093476 ethylene glycol Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- RBNPOMFGQQGHHO-UHFFFAOYSA-N glyceric acid Chemical compound OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940076640 hesperidin methylchalcone Drugs 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 229940027897 ichthammol Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- OIXVKQDWLFHVGR-WQDIDPJDSA-N neomycin B sulfate Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO OIXVKQDWLFHVGR-WQDIDPJDSA-N 0.000 description 1
- 229940053050 neomycin sulfate Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000010665 pine oil Substances 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229910000648 terne Inorganic materials 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- 229940036248 turpentine Drugs 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000001643 venotonic effect Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0014—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
- A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S602/00—Surgery: splint, brace, or bandage
- Y10S602/904—Film-forming bandage material
Definitions
- NEW SURGICAL DRESSING The invention concerns a new surgical dressing applicable to the skin in the form of an ointment or cream which, on drying, leaves a solid, but flexible film.
- the dried film peels off.
- the dried film is not sufficiently flexible.
- the dressing is difficult to remove with water.
- the dressing is likely to stain garments when coloring substances, such as dyestuffs or tar, are present.
- the dressing does not allow cutaneous perspiration to take place.
- the dressing is too occlusive and does not let skin breath.
- the present invention solves these difficult problems and makes it possible to secure firmly over a small or large area of any part of the body a special dressing which can be readily positioned and removed.
- a considerable advantage of the new dressing resides in that it can be positioned in an extremely short time, for example of the order of 1 minute, and that is removed simply by dissolving it in water, accompanied by very light rubbing, so that the patient does not suffer any pain (on the other hand, the dressing will remain intact even when wetted as long as it is not rubbed).
- Another advantage of the new dressing according to the invention is the possibility which it offers for containing the desired medicament substances and the dressing permits only slow penetration of the medicament to the patient thus avoiding overall resorption.
- this new dressing can cover the skin and retain in position thereon an appropriate medicament, or even itself contain, in dispersion or solution, one or more suitable medicament substances.
- Other advantages include absence of staining, intimate adherence to dermatosis and the ability to permit both cutaneous perspiration and breathing of the covered skin.
- the excipient of the new dressing may contain notably various active principles employed in dermatology, such as antibiotics and other bactericides, disinfectants, cicatrizants, cellular regeneration elements, antimycotics, anti-inflammatory agents, venotonic agents, anticoagulants, coagulants, analgesics, antiallergic diffusion products, keratolytics, revulsants, radio protectors, ichthammol, antisolar agents, antitussives, decontractants, local anaesthetics, sulphonamides, benzyl alcohol, quaternary ammonium compounds, zinc salts, enzymes, tars, coloring agents, and the like.
- active principles employed in dermatology such as antibiotics and other bactericides, disinfectants, cicatrizants, cellular regeneration elements, antimycotics, anti-inflammatory agents, venotonic agents, anticoagulants, coagulants, analgesics, antiallergic diffusion products, keratolytics, revulsants, radio protectors, icht
- the excipient according to the invention is very suitable for the preparation of a paste based upon a radiological protector, for example Pb powder, Pb silicate or sulfate or the like.
- the dressing excipient according to the invention is composed essentially of vinyl pyrrolidone-vinylacetate copolymer which is soluble in a lower aqueous alcohol and which is capable of giving a film on the skin; a thixotropic agent of a triglyceride of hydropylated fatty acids having 12-24 carbon atoms, preferably l2-hydroxystearic acid glyceride; a solvent for the resin, which fairly rapidly dries on the skin, namely aqueous alcohol; and a plasticizer preferably of polyoxyethylene-glycol and/or acetoglycerides.
- the proportions of these constituents are such that the product obtained is in the form of an ointment or a cream, depending upon the concentration.
- the thixotropic agent may also comprise other materials known to produce thixotropic efiects, as referred to, for example, in Modern Plastics Encyclopedia, 1968, page 396.
- Such agents may be notable mineral, organic or mixed compounds, namely siliceous minerals, more particularly based on aluminum, magnesium and/or silicon and comprising hydroxy groups; kaolin; colloidal or microcrystalline silica; clays, above all of the montmorillonite group, notably bentonite, optionally modified by organic compounds such as amines or compounds having onium groups which replace some of the cations (Na) of the bentonite; oxides; carbonates or sulfates of alkaline-earth metals; metallic stearates, more particularly those of aluminum, zinc or calcium; waxes; etc; those preferred are cationic bentonite, kaolin and/or colloidal silic, particularly in extra fine form, e.g., aerosil.
- such other thixotropic agents may comprise up to percent of the total thixotropic material present, the remainder being the triglyceride, preferably the triglyceride of l2-hydroxystearic acid.
- the thixotropic agent performs a very special and important function in the dressing according to the invention, since it imparts to the product the mechanical stability necessary for obtaining an ointment. Without this constituent, theproduct would form a too-fluid mixture; owing to its presence, the ointment acquires, immediately after it has been spread onto the skin, appropriate rigidity and hardness, due to the thixotropic effect of the adjuvant.
- the thixotropic agent more particularly triglyceride of hydroxystearic acid, imparts to the film obtained the desired resistance to water and to mechanical actions.
- the proportion of thixotropic agent in the dressing composition may vary somewhat; generally, it is from 15 to 35 parts by weight based on l00 parts by weight of the resin, and preferably it comprises l8-27 parts by weight.
- the plasticizer has the function of preventing the film from pulling the skin and flaking.
- plasticizer there may be employed: (l) a polyoxyalkylcne polyol (ether), such as polyoxyethylene glycol; (2) a mixed ester of polyol, i.e., a combination of a polyol (glycol, glycerine) with two different organic carboxylic acids, one of which is a fatty acid and the other a lower aliphatic acid; (3) a mixture of an ether (l) with an ester (2).
- the mixed esters can be illustrated by the following formulas in the cases of ethylene-glycol and of glycerine taken as polyols:
- R-CCOH is an aliphatic lower acid, such as for example acetic, propionic, butyric, etc., up to six carbon atoms
- R'- COOl-l is a fatty acid, for instance oleic, stearic, palmitic, etc.
- acetoglycerides that is mixed esters of glycerine as above, in which RCOO- is acetic group and R'COO- fatty acid moiety, mainly oleic.
- a particularly advantageous plasticizer is the diacetic ester of glyceryl monoleate. These materials function very well and are harmless to the skin.
- the proportion of plasticizer may be from 20 to 40 parts per 100 parts resin and preferably from 25 to 30 parts based on the weight of the resin.
- the solvent most commonly employed in pharmacy being ethyl alcohol, it is ethanol (95) [95 percent by volume] which constitutes the most suitable solvent for the excipient according to the invention.
- the total quantity of solvent is generally of the same order, i.e., about 60 to 120 parts per 100 parts resin, as that of the resin. However, the preferred quantity is 7080 parts solvent per 100 parts resin.
- the specific resin for use according to the invention is a copolymer of vinylpyrrolidone and vinyl acetate, containing by weight 20 to 80 percent of vinylpyrrolidone and 80 to 20 percent of vinylacetate. Best copolymers are those which contain 30 to 70 percent of vinylpyrrolidone with 70 to 30 percent vinylacetate. It has been found that particularly suitable excipient is obtained when one mixes a copolymer rich in vinylpyrrolidone (e.g., 60 to 70 percent vinylpyrrolidone) with a copolymer poor in vinylpyrrolidone (for instance having 30 to 40 percent of vinylpyrrolidone).
- a preferred dressing contains a mixture of copolymers, such that in 100 parts of the mixture there are:
- the new excipient is prepared by very intimately mixing the four kinds or more of the above-indicated compounds. It is to be noted that the finer the dispersion of the triglyceride of 12- hydroxystearic acid (with or without added bentonite) in the product formed, the more the latter imparts a favorable thixotropy to the formation of the dressing on the skin. As indicated above, various medicament substances may be incorporated in the excipient; this incorporation may take place during the preparation, or after the latter, by mixing the medicaments with the ointment already formed.
- EXAMPLE 1 Preparation of an excipient according to the invention. The weights are in grams.
- PVPE vinyl polyvinylpyrrolidone acetate
- PVIAV vinyl polyvinylpyrrolidone acetate
- egg yolk alcohclate 15%) in the course of the manufacture, it is necessary to add a certain quantity of 95 ethyl alcohol in order to counteract the losses 1% the evaporation of the solvent.
- 2% 630 and the triglycerides of l2-hydroxystearic acid are first introduced. The two powders are first well mixed by stirring and the acetoglyceride LC and the egg yolk alcoholate are added.
- the mixture is stirred until a paste is obtained, whereafter the aerosil (colloidal silica) is added in proportions of 4 percent to 7 percent, and then the water.
- the mixture is stirred until all the lumps have disappeared.
- the polyoxyethylene glycol (Carbowax) is added and then the alcohol, if necessary, and finally the PVP/VA 335.
- EXAMPLE 2 Formula (21) In 100 parts by weight of excipient prepared in accordance with example l is incorporated the following mixture:
- Biclotymol i.e., 2,2-methylene-bis (4- chlorothymol) 0.2 part of parachlorphenoxytol 0.2 part of vitamin A acetate 100,000 IU/g
- lignocain hydrochloride 6.0 parts of ethyl alcohol 0.12 part of 2.5 percent eosin solution.
- Formula (b) For an ointment for use by sportsmen.
- Glycerol ether of ortho-creso1 10 g. Methyl nicotate I g. Escin (anti-inflammatory substance emanating from horsechestnut) 1 g. Glycol salicylate 5 g. Excipient q.s.7o
- Formula (c) A product for application to the chest for coughing.
- Example 4 0.10 to 1 g. of Biclotymol 0. 10 to 1 g. of triamcinolone acetonide (Example 5) 0.10 to l g. of neomycin sulfate (expressed as base) (Example 6) 5 to 20 g. of undecylenic acid (Example 7) 5 to 10 g. of flavonoids (Example 8) 1 to 5 g.
- An excipient according to claim 1 wherein said thixotropic agent also comprises up to percent thereof of a siliceous mineral material chosen from the group consisting of bentonite, colloidal silica and kaolin.
- An excipient according to claim 1 wherein said thixotropic agent is the triglyceride of l2-hydroxystearic acid.
Abstract
The dressing excipient is composed essentially of vinyl pyrrolidone-vinylacetate copolymer which is soluble in a lower aqueous alcohol and which is capable of giving a film on the skin; a thixotropic agent of a triglyceride of hydroxylated fatty acids having 12-24 carbon atoms, preferably 12-hydroxystearic acid glyceride; a solvent for the resin, which fairly rapidly dries on the skin, namely aqueous alcohol; and a plasticizer of polyoxyethylene-glycol and/or acetoglycerides.
Description
United States Patent inventor Lucien Nouvel 91 Ave. der Ternes, Paris, XVIF France Appl. No. 866,028
Filed Oct. 13, 1969 Patented Sept. 21, 1971 NEW SURGICAL DRESSING 5 Claims, No Drawings int. Cl A611) 17/04, A6lk 15/00, A61115/00 Field 01 Search 128/ l 56,
[56} References Cited UNITED STATES PATENTS 2,804,073 8/1957 Gallienne et a1 128/156 3,214,338 10/1965 Ehrlich 424/78 Primary Examiner-Shep K. Rose Attorney-Browdy and Neimark preferably l2-hydroxystearic acid glyceride; a solvent for the resin, which fairly rapidly dries on the skin, namely aqueous alcohol; and a plasticizer of polyoxyethylene-glycol and/or acetoglycerides.
NEW SURGICAL DRESSING The invention concerns a new surgical dressing applicable to the skin in the form of an ointment or cream which, on drying, leaves a solid, but flexible film.
It is often useful to be able to cover an injured region of the skin with an adhering film in order to maintain it in contact with a medicament substance, because it frequently occurs that known adhesive tapes must be avoided in certain patients because they produce manifestations of intolerance. On the other hand, on certain parts of the body, it is difficult or even impossible to apply an ordinary or adhering dressing. It is also known that difficulties are often encountered in removing a dressing from a painful part; even if there is no manifestation of particular intolerance, the removal may be very painful.
While adhering wound-dressing compositions embodying a water-soluble polymer have been contemplated, and some have even been commercialized, these prior compositions have not been entirely satisfactory and even those commercialized have not found wide usage. These prior compositions inevitably suffer from one or more of the following defects:
1. The drying time for the formation of the protective film is too long.
The film shrinks when drying.
The dried film peels off.
The dried film is not sufficiently flexible.
The dressing is difficult to remove with water.
The dressing is likely to stain garments when coloring substances, such as dyestuffs or tar, are present.
7. There is no sufficiently intimate adherence to dermatosis, and peripheral diffusion, causing secondary inflammation around the dermatosis, frequently occurs.
8. The dressing does not allow cutaneous perspiration to take place.
9. The dressing is too occlusive and does not let skin breath.
10. The medicament contained therewith too rapidly penetrates the patients body.
The present invention solves these difficult problems and makes it possible to secure firmly over a small or large area of any part of the body a special dressing which can be readily positioned and removed. A considerable advantage of the new dressing resides in that it can be positioned in an extremely short time, for example of the order of 1 minute, and that is removed simply by dissolving it in water, accompanied by very light rubbing, so that the patient does not suffer any pain (on the other hand, the dressing will remain intact even when wetted as long as it is not rubbed). Another advantage of the new dressing according to the invention is the possibility which it offers for containing the desired medicament substances and the dressing permits only slow penetration of the medicament to the patient thus avoiding overall resorption. Thus, this new dressing can cover the skin and retain in position thereon an appropriate medicament, or even itself contain, in dispersion or solution, one or more suitable medicament substances. Other advantages include absence of staining, intimate adherence to dermatosis and the ability to permit both cutaneous perspiration and breathing of the covered skin.
The excipient of the new dressing may contain notably various active principles employed in dermatology, such as antibiotics and other bactericides, disinfectants, cicatrizants, cellular regeneration elements, antimycotics, anti-inflammatory agents, venotonic agents, anticoagulants, coagulants, analgesics, antiallergic diffusion products, keratolytics, revulsants, radio protectors, ichthammol, antisolar agents, antitussives, decontractants, local anaesthetics, sulphonamides, benzyl alcohol, quaternary ammonium compounds, zinc salts, enzymes, tars, coloring agents, and the like.
On the other hand, the excipient according to the invention is very suitable for the preparation of a paste based upon a radiological protector, for example Pb powder, Pb silicate or sulfate or the like.
It is known that such efiective dermatological products as tars and various colored substances, for example parachlorophenoxetol, have unpleasant properties; these products stain everything and their stains are difficult to remove. Now, when they are incorporated in the excipient according to the invention, they remain just as effective, but completely cease to stain, since this excipient, which contains tar or coloring agent, forms on the skin a dry, completely nonsoiling film which can readily be removed with water. The application of the invention to this kind of medicament materials therefore affords a considerable advance.
The dressing excipient according to the invention is composed essentially of vinyl pyrrolidone-vinylacetate copolymer which is soluble in a lower aqueous alcohol and which is capable of giving a film on the skin; a thixotropic agent of a triglyceride of hydropylated fatty acids having 12-24 carbon atoms, preferably l2-hydroxystearic acid glyceride; a solvent for the resin, which fairly rapidly dries on the skin, namely aqueous alcohol; and a plasticizer preferably of polyoxyethylene-glycol and/or acetoglycerides.
The proportions of these constituents are such that the product obtained is in the form of an ointment or a cream, depending upon the concentration.
In addition to the essential triglyceride of hydroxylated fatty acid having 12-24 carbon atoms, such as the preferred l2- hydroxystearic acid glyceride or the alternate glycerides of acids such as ricinoleic, ricinostearolic, hydroxypalmitic, hydroxycapric or hydroxy arachidic, the thixotropic agent may also comprise other materials known to produce thixotropic efiects, as referred to, for example, in Modern Plastics Encyclopedia, 1968, page 396. Such agents may be notable mineral, organic or mixed compounds, namely siliceous minerals, more particularly based on aluminum, magnesium and/or silicon and comprising hydroxy groups; kaolin; colloidal or microcrystalline silica; clays, above all of the montmorillonite group, notably bentonite, optionally modified by organic compounds such as amines or compounds having onium groups which replace some of the cations (Na) of the bentonite; oxides; carbonates or sulfates of alkaline-earth metals; metallic stearates, more particularly those of aluminum, zinc or calcium; waxes; etc; those preferred are cationic bentonite, kaolin and/or colloidal silic, particularly in extra fine form, e.g., aerosil. Where used, such other thixotropic agents may comprise up to percent of the total thixotropic material present, the remainder being the triglyceride, preferably the triglyceride of l2-hydroxystearic acid.
The thixotropic agent performs a very special and important function in the dressing according to the invention, since it imparts to the product the mechanical stability necessary for obtaining an ointment. Without this constituent, theproduct would form a too-fluid mixture; owing to its presence, the ointment acquires, immediately after it has been spread onto the skin, appropriate rigidity and hardness, due to the thixotropic effect of the adjuvant. In addition, the thixotropic agent, more particularly triglyceride of hydroxystearic acid, imparts to the film obtained the desired resistance to water and to mechanical actions.
The proportion of thixotropic agent in the dressing composition may vary somewhat; generally, it is from 15 to 35 parts by weight based on l00 parts by weight of the resin, and preferably it comprises l8-27 parts by weight.
The plasticizer has the function of preventing the film from pulling the skin and flaking. As plasticizer there may be employed: (l) a polyoxyalkylcne polyol (ether), such as polyoxyethylene glycol; (2) a mixed ester of polyol, i.e., a combination of a polyol (glycol, glycerine) with two different organic carboxylic acids, one of which is a fatty acid and the other a lower aliphatic acid; (3) a mixture of an ether (l) with an ester (2). The mixed esters can be illustrated by the following formulas in the cases of ethylene-glycol and of glycerine taken as polyols:
where R-CCOH is an aliphatic lower acid, such as for example acetic, propionic, butyric, etc., up to six carbon atoms, and R'- COOl-l is a fatty acid, for instance oleic, stearic, palmitic, etc.
Particularly useful seem acetoglycerides, that is mixed esters of glycerine as above, in which RCOO- is acetic group and R'COO- fatty acid moiety, mainly oleic. A particularly advantageous plasticizer is the diacetic ester of glyceryl monoleate. These materials function very well and are harmless to the skin. The proportion of plasticizer may be from 20 to 40 parts per 100 parts resin and preferably from 25 to 30 parts based on the weight of the resin.
The solvent most commonly employed in pharmacy being ethyl alcohol, it is ethanol (95) [95 percent by volume] which constitutes the most suitable solvent for the excipient according to the invention. The total quantity of solvent is generally of the same order, i.e., about 60 to 120 parts per 100 parts resin, as that of the resin. However, the preferred quantity is 7080 parts solvent per 100 parts resin.
The specific resin for use according to the invention is a copolymer of vinylpyrrolidone and vinyl acetate, containing by weight 20 to 80 percent of vinylpyrrolidone and 80 to 20 percent of vinylacetate. Best copolymers are those which contain 30 to 70 percent of vinylpyrrolidone with 70 to 30 percent vinylacetate. It has been found that particularly suitable excipient is obtained when one mixes a copolymer rich in vinylpyrrolidone (e.g., 60 to 70 percent vinylpyrrolidone) with a copolymer poor in vinylpyrrolidone (for instance having 30 to 40 percent of vinylpyrrolidone). Thus, a preferred dressing, according to the invention, contains a mixture of copolymers, such that in 100 parts of the mixture there are:
25 to 45 and better yet 28 to 38 parts of a copolymer having 60 to 70 percent vinylpyrrolidone, remainder vinylacetate and 75 to 55 and better yet 72 to 62 parts of a copolymer having 30 to 40 percent vinylpyrrolidone, remainder vinylacetate.
The new excipient is prepared by very intimately mixing the four kinds or more of the above-indicated compounds. It is to be noted that the finer the dispersion of the triglyceride of 12- hydroxystearic acid (with or without added bentonite) in the product formed, the more the latter imparts a favorable thixotropy to the formation of the dressing on the skin. As indicated above, various medicament substances may be incorporated in the excipient; this incorporation may take place during the preparation, or after the latter, by mixing the medicaments with the ointment already formed.
The invention is illustrated by the following nonlimiting examples:
EXAMPLE 1 Preparation of an excipient according to the invention. The weights are in grams.
Resin: vinyl polyvinylpyrrolidone acetate (PVP/AV) 630 [60% VP-40% V Acetate] (PVPIAV) 335 [30% VP70% V Acetate] egg yolk alcohclate (15%) in the course of the manufacture, it is necessary to add a certain quantity of 95 ethyl alcohol in order to counteract the losses 1% the evaporation of the solvent. 2% 630 and the triglycerides of l2-hydroxystearic acid are first introduced. The two powders are first well mixed by stirring and the acetoglyceride LC and the egg yolk alcoholate are added. The mixture is stirred until a paste is obtained, whereafter the aerosil (colloidal silica) is added in proportions of 4 percent to 7 percent, and then the water. The mixture is stirred until all the lumps have disappeared. The polyoxyethylene glycol (Carbowax) is added and then the alcohol, if necessary, and finally the PVP/VA 335.
There is thus obtained a very unctuous ointment which can be readily applied to the skin. When used in a thin layer, it dries in less than a minute and gives a film having suitable resistance to abrasion, which is readily soluble in water, which facilitates washing, i.e., removal of the dressing.
EXAMPLE 2 Formula (21) In 100 parts by weight of excipient prepared in accordance with example l is incorporated the following mixture:
0.4 part of Biclotymol, i.e., 2,2-methylene-bis (4- chlorothymol) 0.2 part of parachlorphenoxytol 0.2 part of vitamin A acetate 100,000 IU/g) 0.6 g. of lignocain hydrochloride 6.0 parts of ethyl alcohol 0.12 part of 2.5 percent eosin solution.
Formula (b) For an ointment for use by sportsmen.
Glycerol ether of ortho-creso1 10 g. Methyl nicotate I g. Escin (anti-inflammatory substance emanating from horsechestnut) 1 g. Glycol salicylate 5 g. Excipient q.s.7o
Formula (c) A product for application to the chest for coughing.
lsopropyl myristate 0.25 g. Methyl nicotate 0.25 g. Guaiacyl nlcotate 0.50 g. Eucalyptole 3.0 g. Camphor 0.50 g. Pine oil 2.0 g. Thyme cil 1.0 g. Spirit of turpentine 2.0 g. Thymol essence 0.25 g.
Formula (cl) For blood circulation and massage of aching legs.
Escine 1.0 g. Lysnzyme 1.0 g. Heparin 10,000 1U Hesperidin methyl chalcone 1% Nicotinic acid 2% EXAMPLE 3 From 0.1 to l g. of hydrocortisone acetate is incorporated in the excipient of example 1, which gives an excellent anti-inflammatory dermatological dressing.
EXAMPLES 4 to 8 The following formulas, for g. of excipient of example 1 illustrate some of the dressings comprising medicamental sub stances incorporated in accordance with the invention.
(Example 4) 0.10 to 1 g. of Biclotymol 0. 10 to 1 g. of triamcinolone acetonide (Example 5) 0.10 to l g. of neomycin sulfate (expressed as base) (Example 6) 5 to 20 g. of undecylenic acid (Example 7) 5 to 10 g. of flavonoids (Example 8) 1 to 5 g. of promethazine OTHER EXAMPLES Dihydroxyanthranol 02-10% Salicylic acid 1-20% or more (up w 500% Resorcinol 1-2096 Thioresorcinol 140% Coal tar 1-4066 Vegetable tar 140% Thuya dye 1-2096 Derivative of lead or other radio protector 1-l00% Sulfur 5-30% thereof, upon drying, which consists essentially of, for each 100 parts of a copolymer of vinylpyrrolidone and vinylacetate, 15-35 parts of a thixotropic agent imparting rigidity, hardness and water resistance to the film, of a triglyceride of hydroxylated fatty acid of 12-24 carbon atoms, 20-40 parts of a plasticizer, preventing the film from pulling the skin, selected from the group consisting of the diacetic ester of glyceryl monooleate, polyoxyethylene glycol, and mixtures thereof, and 60-120 parts of an aqueous alcoholic solvent for the resin.
2. An excipient according to claim 1 wherein said thixotropic agent also comprises up to percent thereof of a siliceous mineral material chosen from the group consisting of bentonite, colloidal silica and kaolin.
3. An excipient according to claim 1 wherein said thixotropic agent is the triglyceride of l2-hydroxystearic acid.
4. An excipient according to claim 1, characterized in that the plasticizer consists of the diacetic ester of glyceryl monooleate.
5. An excipient according to claim 1 wherein the solvent is aqueous ethanol.
UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent 3,608. O7O fipiembenlwL Invent Lucien NOUVEL It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:
Column 3, line 73, delete "1%" and insert --due to the--; and
delete "2%" and insert -PVP/VA-.
Signed and sealed this 7th day of March 1 972.
(SEAL) Attest:
EDWARD M.FLETCHER,JR. ROBERT GOTTSGHALK Attesting Officer Commissioner of Patents ORM PC1-1050 (ID-69) USCOMM-OC 60375-969 u 5 GOVERNMENT PRINTING orncs I969 0- 366-334
Claims (4)
- 2. An excipient according to claim 1 wherein said thixotropic agent also comprises up to 80 percent thereof of a siliceous mineral material chosen from the group consisting of bentonite, colloidal silica and kaolin.
- 3. An excipient according to claim 1 wherein said thixotropic agent is the triglyceride of 12-hydroxystearic acid.
- 4. An excipient according to claim 1, characterized in that the plasticizer consists of the diacetic ester of glyceryl monooleate.
- 5. An excipient according to claim 1 wherein the solvent is aqueous ethanol.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR6919036A FR2047874A6 (en) | 1969-06-10 | 1969-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
US3608070A true US3608070A (en) | 1971-09-21 |
Family
ID=9035419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US866028A Expired - Lifetime US3608070A (en) | 1969-06-10 | 1969-10-13 | New surgical dressing |
Country Status (8)
Country | Link |
---|---|
US (1) | US3608070A (en) |
BE (1) | BE734506A (en) |
CA (1) | CA945070A (en) |
CH (1) | CH519341A (en) |
DE (1) | DE1931080B2 (en) |
FR (1) | FR2047874A6 (en) |
GB (1) | GB1279294A (en) |
NL (1) | NL6909365A (en) |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3880158A (en) * | 1974-04-04 | 1975-04-29 | Johnson & Johnson | Spray-spun bandage composition |
US4210633A (en) * | 1978-10-20 | 1980-07-01 | Eli Lilly And Company | Flurandrenolide film formulation |
US4289749A (en) * | 1979-08-14 | 1981-09-15 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing phenylpropanolamine |
US4291014A (en) * | 1979-01-11 | 1981-09-22 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing estradiol diacetate |
WO1982000099A1 (en) * | 1980-07-09 | 1982-01-21 | Key Pharma | Polymeric diffusion matrix for administration of drugs |
EP0107277A1 (en) * | 1982-09-30 | 1984-05-02 | Gaf Corporation | Pliable films of polymeric halogen complexes |
US4479933A (en) * | 1980-02-14 | 1984-10-30 | Vsesojuzny Nauchnoissledovatelsky I Ispytatelny Institut Meditsinskoi Tekhniki | Composition for sealing wound surfaces |
US4482533A (en) * | 1982-01-11 | 1984-11-13 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing propranolol |
US4482534A (en) * | 1980-12-16 | 1984-11-13 | Forest Laboratories, Inc. | Nitroglycerin preparations |
US4584192A (en) * | 1984-06-04 | 1986-04-22 | Minnesota Mining & Manufacturing Company | Film-forming composition containing an antimicrobial agent and methods of use |
US5128138A (en) * | 1989-07-21 | 1992-07-07 | Izhak Blank | Estradiol compositions and methods for topical application |
US5232703A (en) * | 1989-07-21 | 1993-08-03 | Izhak Blank | Estradiol compositions and methods for topical application |
US5320838A (en) * | 1992-12-21 | 1994-06-14 | Pro Cure Products, Ltd. | Protectant for irritated skin containing polyethyleneglycols, polyvinylether salt anhydride and polyvinylpyrrolidone |
WO1994022504A1 (en) * | 1993-04-05 | 1994-10-13 | Tetra Werke Dr. Rer. Nat. Ulrich Baensch Gmbh | Disinfectant film-forming wound-covering gel |
US5457093A (en) * | 1987-09-18 | 1995-10-10 | Ethicon, Inc. | Gel formulations containing growth factors |
US5558872A (en) * | 1995-03-07 | 1996-09-24 | Healthpoint Medical Limited Partnership | Gelled mineral oil skin protectant |
US5607686A (en) * | 1994-11-22 | 1997-03-04 | United States Surgical Corporation | Polymeric composition |
US5658559A (en) * | 1992-12-16 | 1997-08-19 | Creative Products Resource Associates, Ltd. | Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder |
EP0888141A1 (en) * | 1996-03-12 | 1999-01-07 | Adolor Corporation | Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic conditions therewith |
US6479076B2 (en) | 2001-01-12 | 2002-11-12 | Izhak Blank | Nicotine delivery compositions |
US6716463B1 (en) * | 1997-12-03 | 2004-04-06 | Nippon Suisan Kaisha, Ltd | Coating agent for cooking range heated frozen food comprising core food and layer of coating, and food using the same |
US20070258935A1 (en) * | 2006-05-08 | 2007-11-08 | Mcentire Edward Enns | Water dispersible films for delivery of active agents to the epidermis |
US20070259029A1 (en) * | 2006-05-08 | 2007-11-08 | Mcentire Edward Enns | Water-dispersible patch containing an active agent for dermal delivery |
WO2007132239A2 (en) * | 2006-05-17 | 2007-11-22 | Aston University | Adhesive solution for application to the skin |
US20080057090A1 (en) * | 2006-09-01 | 2008-03-06 | Mcentire Edward Enns | Wrinkle masking film composition for skin |
US20080085972A1 (en) * | 2006-10-05 | 2008-04-10 | O'brien Emmett Patrick | Switchable adhesive article for attachment to skin and method of using the same |
US20170283622A1 (en) * | 2015-04-21 | 2017-10-05 | Behr Process Corporation | Decorative coating compositions |
US9821084B2 (en) | 2005-02-15 | 2017-11-21 | Virginia Commonwealth University | Hemostasis of wound having high pressure blood flow using kaolin and bentonite |
US9867898B2 (en) | 2006-05-26 | 2018-01-16 | Z-Medica, Llc | Clay-based hemostatic agents |
US9889154B2 (en) | 2010-09-22 | 2018-02-13 | Z-Medica, Llc | Hemostatic compositions, devices, and methods |
US10314935B2 (en) | 2009-01-07 | 2019-06-11 | Entrotech Life Sciences, Inc. | Chlorhexidine-containing antimicrobial laminates |
US10960100B2 (en) | 2012-06-22 | 2021-03-30 | Z-Medica, Llc | Hemostatic devices |
US11039615B2 (en) | 2014-04-18 | 2021-06-22 | Entrotech Life Sciences, Inc. | Methods of processing chlorhexidine-containing polymerizable compositions and antimicrobial articles formed thereby |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1028621A (en) * | 1972-05-19 | 1978-03-28 | Kent J. Valan | Powder melts and emulsions of a poly (n-vinyl lactam) and an unsaturated fatty acid component |
DE2432925C3 (en) * | 1974-07-05 | 1985-11-21 | Schering AG, 1000 Berlin und 4709 Bergkamen | Film-shaped medicinal products |
DE2514099A1 (en) * | 1975-03-29 | 1976-10-14 | Henkel & Cie Gmbh | COSMETIC EMULSIONS OF THE WATER-IN-OIL TYPE AND THEIR PRODUCTION |
DE2514100A1 (en) * | 1975-03-29 | 1976-10-07 | Henkel & Cie Gmbh | COSMETIC EMULSIONS OF THE WATER-IN-OIL TYPE AND THEIR PRODUCTION |
LU78831A1 (en) * | 1978-01-06 | 1979-09-06 | Oreal | COMPOSITION FOR CLEANING THE SKIN |
FR2463617A1 (en) * | 1979-08-20 | 1981-02-27 | Thorel Jean Noel | NOVEL SLIMMING COMPOSITIONS BASED ON MUCOPOLYSACCHARIDES AND ESCINE |
LU83710A1 (en) * | 1981-10-23 | 1983-06-07 | Cird | POLYMERIC DIFFUSION MATRIX BASED ON ANTHRALINE OR ONE OF ITS DERIVATIVES AND ITS APPLICATION IN THE TREATMENT OF SKIN DISEASES |
EP0124665B1 (en) * | 1983-05-05 | 1988-04-20 | Quinoderm Limited | Dermatological compositions |
FR2566270A1 (en) * | 1984-06-25 | 1985-12-27 | Ausonia Farma Srl | Pharmaceutical dosage forms in gel form, for the topical application of active principles |
DE3438005A1 (en) * | 1984-10-17 | 1986-04-17 | Röhm GmbH, 6100 Darmstadt | PHARMACEUTICAL AGENT FOR LOCAL THERAPY OF PSORIASIS |
DE3612305A1 (en) * | 1986-04-11 | 1987-10-22 | Roehm Pharma Gmbh | LIQUID MEDICINE FOR THERAPY OF PSORIASIS BASED ON FILM-FORMING POLYMERS |
EP0289900A1 (en) * | 1987-04-30 | 1988-11-09 | Abbott Laboratories | Topical antibacterial compositions |
US5082656A (en) * | 1987-04-30 | 1992-01-21 | Abbott Laboratories | Topical antibacterial compositions containing penetration enchancers |
NZ226171A (en) * | 1987-09-18 | 1990-06-26 | Ethicon Inc | Gel formulation containing polypeptide growth factor |
FR2642976B1 (en) * | 1989-02-15 | 1997-11-14 | Ramond Gerard | CUTANEOUS CONDUCTIVE VEIL FOR APPLYING CURRENTS TO A SUBJECT FOR A THERAPEUTIC OR AESTHETIC PURPOSE, AND APPARATUS USING SUCH A VEIL |
DE4006628A1 (en) * | 1990-03-06 | 1990-11-22 | Bernd Dr Med Ditter | Fabric pad such as plaster - is impregnated with materials such as anti-allergens, or for treating inflammation, itching or stings in skin |
DE19833177A1 (en) * | 1998-07-23 | 2000-01-27 | Labtec Gmbh | Rapidly acting plaster preparation for treating irritation due to nettle stings or insect bites, preferably containing menthol and benzocaine |
FR2799369B1 (en) * | 1999-10-08 | 2001-12-21 | Oreal | COMBINATION OF ESCINE AND DEXTRAN SULFATE AND THE USE THEREOF |
US8907153B2 (en) | 2004-06-07 | 2014-12-09 | Nuvo Research Inc. | Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same |
CN107233607B (en) * | 2017-06-27 | 2020-03-31 | 东莞御治医疗器械有限公司 | Preparation method of wound surface protection film material |
-
1969
- 1969-06-10 FR FR6919036A patent/FR2047874A6/fr not_active Expired
- 1969-06-13 BE BE734506D patent/BE734506A/xx not_active IP Right Cessation
- 1969-06-18 CA CA054,707*7A patent/CA945070A/en not_active Expired
- 1969-06-19 DE DE1931080A patent/DE1931080B2/en active Granted
- 1969-06-19 NL NL6909365A patent/NL6909365A/xx unknown
- 1969-06-19 CH CH937069A patent/CH519341A/en not_active IP Right Cessation
- 1969-06-19 GB GB31045/69A patent/GB1279294A/en not_active Expired
- 1969-10-13 US US866028A patent/US3608070A/en not_active Expired - Lifetime
Cited By (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3880158A (en) * | 1974-04-04 | 1975-04-29 | Johnson & Johnson | Spray-spun bandage composition |
US4210633A (en) * | 1978-10-20 | 1980-07-01 | Eli Lilly And Company | Flurandrenolide film formulation |
US4291014A (en) * | 1979-01-11 | 1981-09-22 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing estradiol diacetate |
US4470962A (en) * | 1979-08-14 | 1984-09-11 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix |
US4292301A (en) * | 1979-08-14 | 1981-09-29 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing ephedrine |
US4292303A (en) * | 1979-08-14 | 1981-09-29 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing clonidine |
US4292302A (en) * | 1979-08-14 | 1981-09-29 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing terbutaline |
US4294820A (en) * | 1979-08-14 | 1981-10-13 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing phenylephrine |
US4321252A (en) * | 1979-08-14 | 1982-03-23 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing ester derivatives of estradiol |
US4492685A (en) * | 1979-08-14 | 1985-01-08 | Key Pharmaceuticals, Inc. | Protective skin matrix |
US4289749A (en) * | 1979-08-14 | 1981-09-15 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing phenylpropanolamine |
US4291015A (en) * | 1979-08-14 | 1981-09-22 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing a vasodilator |
US4479933A (en) * | 1980-02-14 | 1984-10-30 | Vsesojuzny Nauchnoissledovatelsky I Ispytatelny Institut Meditsinskoi Tekhniki | Composition for sealing wound surfaces |
WO1982000099A1 (en) * | 1980-07-09 | 1982-01-21 | Key Pharma | Polymeric diffusion matrix for administration of drugs |
US4482534A (en) * | 1980-12-16 | 1984-11-13 | Forest Laboratories, Inc. | Nitroglycerin preparations |
US4482533A (en) * | 1982-01-11 | 1984-11-13 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing propranolol |
EP0107277A1 (en) * | 1982-09-30 | 1984-05-02 | Gaf Corporation | Pliable films of polymeric halogen complexes |
US4584192A (en) * | 1984-06-04 | 1986-04-22 | Minnesota Mining & Manufacturing Company | Film-forming composition containing an antimicrobial agent and methods of use |
US5457093A (en) * | 1987-09-18 | 1995-10-10 | Ethicon, Inc. | Gel formulations containing growth factors |
US5128138A (en) * | 1989-07-21 | 1992-07-07 | Izhak Blank | Estradiol compositions and methods for topical application |
US5232703A (en) * | 1989-07-21 | 1993-08-03 | Izhak Blank | Estradiol compositions and methods for topical application |
US5658559A (en) * | 1992-12-16 | 1997-08-19 | Creative Products Resource Associates, Ltd. | Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder |
US5320838A (en) * | 1992-12-21 | 1994-06-14 | Pro Cure Products, Ltd. | Protectant for irritated skin containing polyethyleneglycols, polyvinylether salt anhydride and polyvinylpyrrolidone |
WO1994022504A1 (en) * | 1993-04-05 | 1994-10-13 | Tetra Werke Dr. Rer. Nat. Ulrich Baensch Gmbh | Disinfectant film-forming wound-covering gel |
US5607686A (en) * | 1994-11-22 | 1997-03-04 | United States Surgical Corporation | Polymeric composition |
US5558872A (en) * | 1995-03-07 | 1996-09-24 | Healthpoint Medical Limited Partnership | Gelled mineral oil skin protectant |
EP0888141A1 (en) * | 1996-03-12 | 1999-01-07 | Adolor Corporation | Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic conditions therewith |
EP0888141A4 (en) * | 1996-03-12 | 2001-01-17 | Adolor Corp | Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic conditions therewith |
US6716463B1 (en) * | 1997-12-03 | 2004-04-06 | Nippon Suisan Kaisha, Ltd | Coating agent for cooking range heated frozen food comprising core food and layer of coating, and food using the same |
US6479076B2 (en) | 2001-01-12 | 2002-11-12 | Izhak Blank | Nicotine delivery compositions |
US9821084B2 (en) | 2005-02-15 | 2017-11-21 | Virginia Commonwealth University | Hemostasis of wound having high pressure blood flow using kaolin and bentonite |
US11167058B2 (en) | 2005-02-15 | 2021-11-09 | Virginia Commonwealth University | Hemostasis of wound having high pressure blood flow |
US20070258935A1 (en) * | 2006-05-08 | 2007-11-08 | Mcentire Edward Enns | Water dispersible films for delivery of active agents to the epidermis |
US20070259029A1 (en) * | 2006-05-08 | 2007-11-08 | Mcentire Edward Enns | Water-dispersible patch containing an active agent for dermal delivery |
WO2007132239A2 (en) * | 2006-05-17 | 2007-11-22 | Aston University | Adhesive solution for application to the skin |
WO2007132239A3 (en) * | 2006-05-17 | 2008-05-15 | Univ Aston | Adhesive solution for application to the skin |
US20090209685A1 (en) * | 2006-05-17 | 2009-08-20 | Alan Amass | Adhesive Solution for Application to the Skin |
US11123451B2 (en) | 2006-05-26 | 2021-09-21 | Z-Medica, Llc | Hemostatic devices |
US10960101B2 (en) | 2006-05-26 | 2021-03-30 | Z-Medica, Llc | Clay-based hemostatic agents |
US10086106B2 (en) | 2006-05-26 | 2018-10-02 | Z-Medica, Llc | Clay-based hemostatic agents |
US9867898B2 (en) | 2006-05-26 | 2018-01-16 | Z-Medica, Llc | Clay-based hemostatic agents |
US20080057090A1 (en) * | 2006-09-01 | 2008-03-06 | Mcentire Edward Enns | Wrinkle masking film composition for skin |
US7879942B2 (en) | 2006-10-05 | 2011-02-01 | Eastman Chemical Company | Switchable adhesive article for attachment to skin and method of using the same |
US20080085972A1 (en) * | 2006-10-05 | 2008-04-10 | O'brien Emmett Patrick | Switchable adhesive article for attachment to skin and method of using the same |
US10314935B2 (en) | 2009-01-07 | 2019-06-11 | Entrotech Life Sciences, Inc. | Chlorhexidine-containing antimicrobial laminates |
US9889154B2 (en) | 2010-09-22 | 2018-02-13 | Z-Medica, Llc | Hemostatic compositions, devices, and methods |
US11007218B2 (en) | 2010-09-22 | 2021-05-18 | Z-Medica, Llc | Hemostatic compositions, devices, and methods |
US10960100B2 (en) | 2012-06-22 | 2021-03-30 | Z-Medica, Llc | Hemostatic devices |
US11559601B2 (en) | 2012-06-22 | 2023-01-24 | Teleflex Life Sciences Limited | Hemostatic devices |
US11039615B2 (en) | 2014-04-18 | 2021-06-22 | Entrotech Life Sciences, Inc. | Methods of processing chlorhexidine-containing polymerizable compositions and antimicrobial articles formed thereby |
US10118864B2 (en) * | 2015-04-21 | 2018-11-06 | Behr Process Corporation | Decorative coating compositions |
US20170283622A1 (en) * | 2015-04-21 | 2017-10-05 | Behr Process Corporation | Decorative coating compositions |
Also Published As
Publication number | Publication date |
---|---|
DE1931080B2 (en) | 1978-04-20 |
GB1279294A (en) | 1972-06-28 |
BE734506A (en) | 1969-12-15 |
FR2047874A6 (en) | 1971-03-19 |
CA945070A (en) | 1974-04-09 |
DE1931080A1 (en) | 1970-12-23 |
CH519341A (en) | 1972-02-29 |
NL6909365A (en) | 1970-12-22 |
DE1931080C3 (en) | 1978-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3608070A (en) | New surgical dressing | |
DE69535737T2 (en) | PLASTER FOR EXTERNAL APPLICATION | |
ES2829386T3 (en) | Transdermal administration patch | |
KR100449939B1 (en) | Tranilast-containing external agent and its production method | |
US20030027833A1 (en) | Compositions and delivery systems for administration of a local anesthetic agent | |
DE3131610A1 (en) | "COATING WITH A CONTENT OF MICRO-ENCAPSULATED NITROGLYZERINE, SUITABLE FOR PERCUTANTLY ADMINISTRATION OF NITROGLYZERINE" | |
DE3710293A1 (en) | WATERPROOF SUN PROTECTION COMPOSITION | |
SI9012260B (en) | Process for preparation of transdermal therapeutic systems containing buprenorphine as the active component | |
JPH07258060A (en) | Skin whitening patch | |
NZ209843A (en) | Transdermal delivery system for administration of nitroglycerin | |
JP2008308453A (en) | Gel composition and its use | |
JP2004524421A (en) | Film-forming composition for topical application and its use for delivery of active agents | |
KR101440318B1 (en) | Patch composition for skin and method for preparing patch for skin using the same | |
SE9202066L (en) | PROCATEROL-CONTAINING PREPARATION FOR SKIN APPLICATION | |
SK114199A3 (en) | Nimesulide gel systems for topical use | |
EP0514794A1 (en) | Plaster preparation | |
KR100708060B1 (en) | Cosmetic composition for removing blackheads on the skin containing oil and surfactant | |
JP5319950B2 (en) | Aqueous patch containing butenafine hydrochloride | |
TWI514999B (en) | Transdermal absorption preparation | |
JPS6034923B2 (en) | Sponge-like medical band | |
DE10138457B4 (en) | Hygiene products for disinfecting | |
JPS60163811A (en) | External application pharmaceutical containing propranolol | |
KR19980076273A (en) | Film-forming gel composition for transdermal absorption | |
KR100385466B1 (en) | Active-agent delivery system comprising, on a film structure, a composition based on a salicylic acid derivative, and its uses | |
JPH0555485B2 (en) |